Exact Mass: 421.0022346
Exact Mass Matches: 421.0022346
Found 42 metabolites which its exact mass value is equals to given mass value 421.0022346,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Bendroflumethiazide
C15H14F3N3O4S2 (421.03778000000005)
Bendroflumethiazide is only found in individuals that have used or taken this drug. It is a thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
3,4-Dimethoxy-N-(4-(3-nitrophenyl)thiazol-2-yl)benzenesulfonamide
N-[4-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]phenyl]-4-methylthiadiazole-5-carboxamide
C15H9F6N5OS (421.04319760000004)
N-[4-[3,5-Bis(trifluoromethyl)pyrazol-1-yl]phenyl]-4-methylthiadiazole-5-carboxamide
C15H9F6N5OS (421.04319760000004)
Leukadherin-1
C22H15NO4S2 (421.04424700000004)
BENDROFLUMETHIAZIDE
C15H14F3N3O4S2 (421.03778000000005)
C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
YM-58483
C15H9F6N5OS (421.04319760000004)
5-O-tert-butyl 1-O-ethyl 3-iodo-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-1,5-dicarboxylate
C14H20IN3O4 (421.04985100000005)
(2,2,2-TRIFLUORO-ACETYLAMINO)-ACETICACIDETHYLESTER
1-(carboxymethyl)-3-methylimidazolium bis[(trifluoromethyl)sulfonyl]imide
C8H9F6N3O6S2 (420.98369660000003)
2-(3-bromo-5-chlorophenyl )-4,6-diphenyl-1,3,5-triazine
C21H13BrClN3 (420.99813080000007)
PANTOPRAZOLE N-OXIDE SODIUM SALT
C16H14F2N3NaO5S (421.05198980000006)
5-Bromo-6-chloro-3-indolylb-D-glucuronide
C14H13BrClNO7 (420.9563878000001)
Aldose reductase-IN-1
C17H10F3N5O3S (421.04564260000006)
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C72880 - Aldose Reductase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(E)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoicacid
C22H15NO4S2 (421.04424700000004)
5-Bromo-4-chloro-3-indolyl beta-d-glucuronide
C14H13BrClNO7 (420.9563878000001)
An indolyl carbohydrate that is the beta-D-glucuronide of indoxyl in which the indole moiety is substituted at positions 4 and 5 by chlorine and bromine, respectively
6-chloro-N-[3-[(2-chlorophenyl)sulfamoyl]phenyl]-3-pyridinecarboxamide
1-(5-Bromo-pyridin-2-yl)-3-[2-(6-fluoro-2-hydroxy-3-propionyl-phenyl)-cyclopropyl]-urea
5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide
Picolinic acid, chromium salt
C18H15CrN3O6 (421.03659100000004)
D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents
2-(2,6-Dichlorophenyl)acetic acid [2-oxo-2-[4-(trifluoromethoxy)anilino]ethyl] ester
C17H12Cl2F3NO4 (421.00954480000007)
[5-(4-Bromophenyl)-3-(2-hydroxyphenyl)-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone
N-[2-[(2-chlorophenyl)methylthio]-4-oxo-1H-pyrimidin-6-yl]-4-methylbenzenesulfonamide
C18H16ClN3O3S2 (421.03215760000006)
5-bromo-4-chloro-3-indolyl alpha-D-glucuronide
C14H13BrClNO7 (420.9563878000001)
Nelonemdaz (potassium)
C15H7F7KNO3 (420.99512160000006)
Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA- and free radical-induced cell death[1][2].
VU 0364439
VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM. IC50 Value: 19.8 nM(EC50) Target: mGluR in vitro: in vivo: VU 0364439 possess less than ideal PK properties preventing their use as in vivo tools. It shows better stability in HLM (63\% remaining) than RLM (2\% remaining).
1-caffeoyl galactose-6-sulphate
C15H17O12S? (421.0440702000001)
{"Ingredient_id": "HBIN002429","Ingredient_name": "1-caffeoyl galactose-6-sulphate","Alias": "NA","Ingredient_formula": "C15H17O12S?","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2901","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
n'-{3-[4-(2-aminoethyl)-2,6-dibromophenoxy]propyl}ethanediamide
C13H17Br2N3O3 (420.96365720000006)